SAB Biotherapeutics To Present SAB-142 Phase 1 Data In Type 1 Diabetes At EASD Meeting September 28-30
Share
Why It Matters
SAB Biotherapeutics will show early study results for a diabetes medicine. Watch to see if doctors think the treatment is safe and working.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.